Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS AG Successfully Completes Rights Offering and Private Placement

Published: Monday, October 28, 2013
Last Updated: Monday, October 28, 2013
Bookmark and Share
Company plans to use EUR 2.7 million to finance its operating business and further growth.

SYGNIS AG has announced that the Company has successfully completed its rights offering. The subscription price was € 2.65 per share.

New shares that were not subscribed in the course of the rights offering by existing shareholders were offered to selected German and international institutional investors in a private placement at a purchase price equivalent to the subscription price. In the transaction 1,019,309 new shares against cash were subscribed.

The Management Board, with the approval of the Supervisory Board, has resolved to increase the Company’s share capital from € 9,364,258.00 to € 10,383,567.00 by issuing 1,019,309 new shares.

The offering utilizes existing authorized capital created by resolution at the Annual General Meeting on August 28, 2013. The new shares carry full dividend rights as of January 1, 2013.

“We welcome our new shareholders and are very thankful for their trust in the new business direction of SYGNIS,” stated Pilar de la Huerta, CEO and CFO of SYGNIS AG. “SYGNIS is a key player in the fast growing market of DNA amplification and sequencing. With the first commercial agreement around SYGNIS’ core technology QualiPhi® with QIAGEN, the world leading provider of sample and assay technologies and a full pipeline with potential blockbuster products for next generation sequencing applications, SYGNIS is best positioned to benefit from the high growth rates we are seeing in gene-based personalized healthcare, molecular diagnostics and epigenetics. The transaction is in our view in the best interest of the Company and its shareholders as it provides the Company with the financial flexibility needed to further execute on its business plans and closes the gap to break-even expected in 2014.”

SYGNIS plans to use the gross proceeds of EUR 2.7 million to finance its operating business and further growth.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS AG Signs Distribution Agreement with LABGENE Scientific
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Friday, September 18, 2015
SYGNIS AG Signs Non-Exclusive Distribution Agreement with GeneWorks Pty Ltd
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Tuesday, August 25, 2015
SYGNIS AG Signs Distribution Agreement with Chinese Nanodigmbio Co. Ltd.
Distribution agreement covers the entire SYGNIS portfolio of powerful tools addressing key challenges in NGS and single cell analysis.
Saturday, August 22, 2015
SYGNIS Signs Initial Non-Exclusive Distribution Agreement with BioCat
TruePrime™ Single Cell WGA kit to be launched early 2015.
Tuesday, December 30, 2014
SYGNIS Reports Financial Results for a Successful Fiscal Year 2013
First products launched based on QualiPhi® now renamed SensiPhi® in early 2014.
Wednesday, April 02, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Antibiotics Discovered While Sifting Through Human Microbiome
Researchers identify genes in a microbe’s genome that produce antibiotic compounds, then synthesize them without the need for bacterial culture.
A Genome-wide View of Human DNA Viruses
In this study, Duplex sequencing was used to accurately analyse the genome-wide rate of spontaneous mutation of human adenovirus C5 (HAdv5).
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!